ArticleBMJ open2025

Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol.

Beibei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.